Remi A Nout

Summary

Affiliation: Leiden University Medical Center
Country: The Netherlands

Publications

  1. doi request reprint Improved risk assessment of endometrial cancer by combined analysis of MSI, PI3K-AKT, Wnt/β-catenin and P53 pathway activation
    Remi A Nout
    Department of Clinical Oncology, Leiden University Medical Center, The Netherlands
    Gynecol Oncol 126:466-73. 2012
  2. doi request reprint Five-year quality of life of endometrial cancer patients treated in the randomised Post Operative Radiation Therapy in Endometrial Cancer (PORTEC-2) trial and comparison with norm data
    Remi A Nout
    Department of Clinical Oncology, Leiden University Medical Center, Leiden, The Netherlands
    Eur J Cancer 48:1638-48. 2012
  3. pmc The in- or exclusion of non-breast cancer related death and contralateral breast cancer significantly affects estimated outcome probability in early breast cancer
    R A Nout
    Department of Clinical Oncology, Leiden University Medical Center, P O Box 9600, 2300 RC, Leiden, The Netherlands
    Breast Cancer Res Treat 109:567-72. 2008
  4. doi request reprint Long-term outcome and quality of life of patients with endometrial carcinoma treated with or without pelvic radiotherapy in the post operative radiation therapy in endometrial carcinoma 1 (PORTEC-1) trial
    Remi A Nout
    Department of Clinical Oncology, Leiden University Medical Center, PO PO Box 9600, 2300 RC Leiden, The Netherlands
    J Clin Oncol 29:1692-700. 2011
  5. doi request reprint Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial
    R A Nout
    Department of Clinical Oncology, Leiden University Medical Center, Leiden, Netherlands
    Lancet 375:816-23. 2010
  6. doi request reprint Quality of life after pelvic radiotherapy or vaginal brachytherapy for endometrial cancer: first results of the randomized PORTEC-2 trial
    Remi A Nout
    Department of Clinical Oncology, Leiden University Medical Center, PO Box 9600, 2300 RC Leiden, The Netherlands
    J Clin Oncol 27:3547-56. 2009
  7. doi request reprint Fifteen-year radiotherapy outcomes of the randomized PORTEC-1 trial for endometrial carcinoma
    Carien L Creutzberg
    Department of Clinical Oncology, Leiden University Medical Center, The Netherlands
    Int J Radiat Oncol Biol Phys 81:e631-8. 2011
  8. ncbi request reprint Loss of ARID1A expression and its relationship with PI3K-Akt pathway alterations, TP53 and microsatellite instability in endometrial cancer
    Tjalling Bosse
    Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands
    Mod Pathol 26:1525-35. 2013
  9. ncbi request reprint High concordance of molecular tumor alterations between pre-operative curettage and hysterectomy specimens in patients with endometrial carcinoma
    Ellen Stelloo
    Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands
    Gynecol Oncol 133:197-204. 2014
  10. doi request reprint Long-term clinical outcome of patients with soft tissue sarcomas treated with limb-sparing surgery and postoperative radiotherapy
    Joeke M Felderhof
    Department of Clinical Oncology, Leiden University Medical Center, Leiden, The Netherlands
    Acta Oncol 52:745-52. 2013

Collaborators

Detail Information

Publications12

  1. doi request reprint Improved risk assessment of endometrial cancer by combined analysis of MSI, PI3K-AKT, Wnt/β-catenin and P53 pathway activation
    Remi A Nout
    Department of Clinical Oncology, Leiden University Medical Center, The Netherlands
    Gynecol Oncol 126:466-73. 2012
    ....
  2. doi request reprint Five-year quality of life of endometrial cancer patients treated in the randomised Post Operative Radiation Therapy in Endometrial Cancer (PORTEC-2) trial and comparison with norm data
    Remi A Nout
    Department of Clinical Oncology, Leiden University Medical Center, Leiden, The Netherlands
    Eur J Cancer 48:1638-48. 2012
    ..The current analysis was done to evaluate long-term health related quality of life (HRQL), and compare HRQL of patients to an age-matched norm population...
  3. pmc The in- or exclusion of non-breast cancer related death and contralateral breast cancer significantly affects estimated outcome probability in early breast cancer
    R A Nout
    Department of Clinical Oncology, Leiden University Medical Center, P O Box 9600, 2300 RC, Leiden, The Netherlands
    Breast Cancer Res Treat 109:567-72. 2008
    ..Knowledge of the contribution of non-disease related death or contralateral breast cancer to estimated recurrent disease rate and overall death rate is indispensable for a correct interpretation and comparison of outcome analyses...
  4. doi request reprint Long-term outcome and quality of life of patients with endometrial carcinoma treated with or without pelvic radiotherapy in the post operative radiation therapy in endometrial carcinoma 1 (PORTEC-1) trial
    Remi A Nout
    Department of Clinical Oncology, Leiden University Medical Center, PO PO Box 9600, 2300 RC Leiden, The Netherlands
    J Clin Oncol 29:1692-700. 2011
    ....
  5. doi request reprint Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial
    R A Nout
    Department of Clinical Oncology, Leiden University Medical Center, Leiden, Netherlands
    Lancet 375:816-23. 2010
    ..This study established whether vaginal brachytherapy (VBT) is as effective as pelvic external beam radiotherapy (EBRT) in prevention of vaginal recurrence, with fewer adverse effects and improved quality of life...
  6. doi request reprint Quality of life after pelvic radiotherapy or vaginal brachytherapy for endometrial cancer: first results of the randomized PORTEC-2 trial
    Remi A Nout
    Department of Clinical Oncology, Leiden University Medical Center, PO Box 9600, 2300 RC Leiden, The Netherlands
    J Clin Oncol 27:3547-56. 2009
    ..Vaginal brachytherapy provides a better QOL, and should be the preferred treatment from a QOL perspective...
  7. doi request reprint Fifteen-year radiotherapy outcomes of the randomized PORTEC-1 trial for endometrial carcinoma
    Carien L Creutzberg
    Department of Clinical Oncology, Leiden University Medical Center, The Netherlands
    Int J Radiat Oncol Biol Phys 81:e631-8. 2011
    ....
  8. ncbi request reprint Loss of ARID1A expression and its relationship with PI3K-Akt pathway alterations, TP53 and microsatellite instability in endometrial cancer
    Tjalling Bosse
    Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands
    Mod Pathol 26:1525-35. 2013
    ..These observations suggest that ARID1A is a causative gene, instead of a target gene, of microsatellite instability by having a role in epigenetic silencing of the MLH1 gene in endometrial cancer. ..
  9. ncbi request reprint High concordance of molecular tumor alterations between pre-operative curettage and hysterectomy specimens in patients with endometrial carcinoma
    Ellen Stelloo
    Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands
    Gynecol Oncol 133:197-204. 2014
    ..Therefore, the objective was to determine whether molecular analysis of pre-operative endometrial cancer samples accurately reflects those alterations in the subsequent hysterectomy specimens...
  10. doi request reprint Long-term clinical outcome of patients with soft tissue sarcomas treated with limb-sparing surgery and postoperative radiotherapy
    Joeke M Felderhof
    Department of Clinical Oncology, Leiden University Medical Center, Leiden, The Netherlands
    Acta Oncol 52:745-52. 2013
    ..To evaluate long-term local control, survival, radiation side effects and functional outcome after limb-sparing surgery followed by postoperative radiotherapy (RT) for soft tissue sarcoma (STS)...
  11. pmc The role of radiotherapy in endometrial cancer: current evidence and trends
    Carien L Creutzberg
    Department of Clinical Oncology, Leiden University Medical Center, The Netherlands
    Curr Oncol Rep 13:472-8. 2011
    ..Current ongoing trials are exploring the role of combined RT and chemotherapy, compared to chemotherapy or RT alone...
  12. pmc The clinical approach toward giant cell tumor of bone
    Lizz van der Heijden
    Departments of Orthopedic Surgery, Clinical Oncology, Radiology, and Pathology, Leiden University Medical Center, Leiden, The Netherlands
    Oncologist 19:550-61. 2014
    ..Denosumab was recently registered for unresectable disease. Moderate-dose radiotherapy (40-55 Gy) is restricted to rare cases in which surgery would lead to unacceptable morbidity and RANKL inhibitors are contraindicated or unavailable. ..